triazolam has been researched along with Colitis Gravis in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kusunoki, Y | 1 |
| Ikarashi, N | 1 |
| Hayakawa, Y | 1 |
| Ishii, M | 1 |
| Kon, R | 1 |
| Ochiai, W | 1 |
| Machida, Y | 1 |
| Sugiyama, K | 1 |
1 other study available for triazolam and Colitis Gravis
| Article | Year |
|---|---|
Hepatic early inflammation induces downregulation of hepatic cytochrome P450 expression and metabolic activity in the dextran sulfate sodium-induced murine colitis.
Topics: Animals; Cell Nucleus; Colitis, Ulcerative; Constitutive Androstane Receptor; Cytochrome P-450 Enzym | 2014 |